Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction

Area of Science:

• Cardiology
• Endocrinology
• Public Health

Background:

• Obesity is a major U.S. health concern, significantly increasing the risk of major adverse cardiovascular events (MACE).
• Current obesity management includes lifestyle changes, medications, and surgery, but their impact on MACE risk is evolving.

Purpose of the Study:

• To review the evidence on how different weight loss therapies affect MACE risk.
• To discuss the current landscape and future directions for obesity pharmacotherapy in cardiovascular risk reduction.

Main Methods:

• Literature review of studies on weight loss interventions and their association with MACE.
• Analysis of the efficacy of lifestyle interventions, bariatric surgery, and pharmacotherapies (older vs. newer agents).

Main Results:

• Lifestyle interventions and older obesity medications yield <12% weight loss with no clear MACE benefit.
• Bariatric surgery achieves 20-30% weight loss and significantly reduces MACE risk.
• Newer pharmacotherapies like semaglutide and tirzepatide demonstrate greater weight loss efficacy and are under cardiovascular outcomes trial evaluation.

Conclusions:

• Current practice focuses on lifestyle and managing risk factors, with limited use of obesity medications due to safety and efficacy concerns.
• Emerging evidence for newer obesity pharmacotherapies may expand their role in MACE risk reduction for patients with obesity.